Hydrazinecarboxamide

Hydrazinecarboxamide

SCHEMBL1463300

Cc1cc(Cl)c(OCCO[Si](C)(C)C(C)(C)C)cc1N.NNC(N)=O

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
DHFR P00374 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
S1PR4 O95977 1/20 0.33
OGG1 O15527 1/20 0.32
KDM4E B2RXH2 2/20 0.31
GLA P06280 1/20 0.31
LMNA P02545 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
NPC1 O15118 1/20 0.31
HPGD P15428 1/20 0.31
RAB9A P51151 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1225358 0.89 DHFR (0.39) ALDH1A1DHFRCA12CA1CA2
SCHEMBL3342596 0.81 NNMT (0.35) ALDH1A1DHFRCA12CA1CA2
SCHEMBL1099695 0.78 CA12 (0.36) ALDH1A1DHFRCA12CA1CA2
SCHEMBL1226681 0.74 ALOX5AP (0.32) CA12CA1CA2CA9CA14
SCHEMBL13303932 0.71 ALDH1A1 (0.32) ALDH1A1CYP1A2
Hydrazinecarboxamide SCHEMBL1464009 0.70 KMO (0.36)
SCHEMBL12827315 0.70 DHFR (0.37) ALDH1A1DHFRKMT2ACYP1A2CYP2C19
SCHEMBL1665370 0.70 S1PR4 (0.47) ALDH1A1KMT2ACYP1A2CYP2C19S1PR4
SCHEMBL25259391 0.70 CA12 (0.35) ALDH1A1DHFRCA12CA1CA2
SCHEMBL1665412 0.69 RXRA (0.48) KMT2ACYP2C19KDM4ELMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871760-B2 [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators ROCHE PALO ALTO LLC (US) 2014-10-28 US disclosed
EP-2480545-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 EP disclosed
WO-2011033055-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-24 WO disclosed
US-20110071143-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS BROTHERTON-PLEISS CHRISTINE E 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071143-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS P2RX3, P2RX7, P2RX1 ALDH1A1 1900/4885DHFR 2849/4885CA12 4783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.